FDA.reportPublic FDA data

Oxervate 20 MCG/ML Ophthalmic Solution

RxCUI
2104341
RxNorm name
Oxervate 20 MCG/ML Ophthalmic Solution
Display name
Oxervate 20 MCG/ML Ophthalmic Solution
Full name
Oxervate 20 MCG/ML Ophthalmic Solution
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:39:07

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761094Oxervatecenegermin-bkbj351(a)Rx2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
OXERVATECENEGERMIN-BKBJDomp farmaceutici S.p.A.89e4bfec-d710-40ed-8885-5d13ba46b1cd2025-02-05Warnings, Adverse reactionsExact identifier
rxcui: 2104341

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
89e4bfec-d710-40ed-8885-5d13ba46b1cdOxervate 20 MCG/ML Ophthalmic SolutionSY14These highlights do not include all the information needed to use OXERVATE safely and effectively. See full prescribing information for OXERVATE. OXERVATE ® (cenegermin-bkbj) ophthalmic solution, for topical ophthalmic use Initial U.S. Approval: 201820250205
89e4bfec-d710-40ed-8885-5d13ba46b1cdoxervate 0.002 % Ophthamic SolutionPSN14These highlights do not include all the information needed to use OXERVATE safely and effectively. See full prescribing information for OXERVATE. OXERVATE ® (cenegermin-bkbj) ophthalmic solution, for topical ophthalmic use Initial U.S. Approval: 201820250205
89e4bfec-d710-40ed-8885-5d13ba46b1cdOxervate 0.002 % Ophthamic SolutionSY14These highlights do not include all the information needed to use OXERVATE safely and effectively. See full prescribing information for OXERVATE. OXERVATE ® (cenegermin-bkbj) ophthalmic solution, for topical ophthalmic use Initial U.S. Approval: 201820250205
89e4bfec-d710-40ed-8885-5d13ba46b1cdOxervate 0.02 MG/ML Ophthalmic SolutionSY14These highlights do not include all the information needed to use OXERVATE safely and effectively. See full prescribing information for OXERVATE. OXERVATE ® (cenegermin-bkbj) ophthalmic solution, for topical ophthalmic use Initial U.S. Approval: 201820250205
89e4bfec-d710-40ed-8885-5d13ba46b1cdcenegermin-bkbj 0.02 MG/ML Ophthalmic Solution [Oxervate]SBD14These highlights do not include all the information needed to use OXERVATE safely and effectively. See full prescribing information for OXERVATE. OXERVATE ® (cenegermin-bkbj) ophthalmic solution, for topical ophthalmic use Initial U.S. Approval: 201820250205